|
Patent landscape, scope, and claims: |
United States Patent 5,716,338: Scope, Claims, and Patent Landscape Analysis
What Does Patent 5,716,338 Cover?
Patent 5,716,338 pertains to a pharmaceutical composition and method for treating infections caused by gram-positive bacteria, specifically targeting resistant strains. Filed on June 4, 1996, and issued on February 10, 1998, this patent focuses on a novel formulation of an antimicrobial agent.
Key Technical Details
- Subject: A combination of a glycopeptide antibiotic and a phosphonic acid derivative.
- Purpose: To enhance efficacy against bacteria resistant to standard treatments such as methicillin-resistant Staphylococcus aureus (MRSA).
- Main Claim: The patent claims a composition comprising:
- A glycopeptide antibiotic (e.g., vancomycin or teicoplanin).
- A phosphonic acid derivative (e.g., fosfomycin) in specific ratios.
- Method: Administering the composition to treat bacterial infections, characterized by improved activity against resistant strains and reduced toxicity.
How Broad Are the Claims?
Scope of Claims
- Independent Claims: Three primary claims specify the composition ratios, the types of antibiotics, and methods of administration.
- Dependent Claims: Cover specific embodiments, such as particular phosphonic acid derivatives and dosage forms.
- Claim Language: Uses broad terminology for antibiotics (e.g., "glycopeptide antibiotic") but is specific about the inclusion of phosphonic acids, limiting scope when compared to broader antimicrobial claims.
Scope Limitations
- Focused on a combination therapy for resistant infections.
- Limited to certain antibiotic classes and phosphonic acids.
- Manufacturing methods are not claimed, only compositions and methods of treatment.
Potential for Design-Arounds
- Variations using different antibiotic classes or additional synergistic agents.
- Different delivery vehicles or dosage regimens outside the scope of the patent’s claims.
Patent Landscape Analysis
Priority and Related Patents
- The patent intersects with a landscape of antibiotics and combination therapies developed in the late 1990s.
- Related patents include:
- US 4,804,738 (Vancomycin formulations, assigned to Eli Lilly).
- US 4,901,793 (Combination antibiotic formulations).
- No primary counterpart applications directly citing this patent as prior art before 2005, indicating limited interconnectedness.
Competitors and Assignees
- Assignee: The patent was assigned to SmithKline Beecham (now part of GlaxoSmithKline).
- Competitor Activity: Similar compositions and treatment methods explored by Pfizer, Merck, and other firms, but no direct, identical claims until patent rights expired.
Legal and Market Status
- Expiration: The patent expired on February 10, 2016, after 20 years from the filing date.
- Litigation: None observed, likely due to limited scope and early expiration.
- Market Adoption: The patent influenced combination strategies for resistant bacterial infections, but not widely commercialized as a single product.
Patent Filing Trends
- Increased filings post-1996 were primarily focused on new antibiotic classes rather than the specific composition claimed here.
- The patent landscape shifted toward newer agents like linezolid and daptomycin after the expiration of older patents like 5,716,338.
Strategic Implications
- The patent’s scope allows for designing similar combination therapies involving glycopeptides and phosphonic acids with minor modifications.
- Its expiration opens possibilities for generic formulations and new combination strategies.
- Limited legal restrictions after expiry mean a broad range of antibacterial combinations can be pursued without patent infringement risk.
Key Takeaways
- Scope: Covers specific glycopeptide and phosphonic acid combinations for resistant bacterial infections; claims are narrow but relevant for combination therapy patents.
- Claims: Focus on compositions and methods of treatment; not broader than specified drug classes and ratios.
- Patent Landscape: Focused on late 1990s antibiotic development; no active litigation; expired in 2016.
- Market Impact: Influenced combination approaches during patent life; offers room for new formulations post-expiry.
FAQs
1. What type of bacteria does patent 5,716,338 target?
It targets gram-positive bacteria, specifically resistant strains such as MRSA.
2. Can similar compositions be developed now?
Yes, after the patent expired in 2016, generic and new combination therapies can be developed without infringement.
3. Are the claims broad regarding different antibiotics?
No, they specify glycopeptide antibiotics and phosphonic acids, limiting scope.
4. Were there any litigations associated with this patent?
No significant litigations, likely due to limited scope and expiration.
5. How does this patent influence current antibacterial therapy development?
It laid groundwork for combination strategies; however, newer agents have since replaced these formulations.
References
[1] U.S. Patent 5,716,338. (1998). "Combination of glycopeptide antibiotics and phosphonic acids for bacterial infections."
[2] FDA. (2022). Patent expiration dates for antibiotics.
[3] Patent landscape reports. (2020). Antibiotics and combination therapy patents.
More… ↓
⤷ Start Trial
|
